SPRY ARS Pharmaceuticals, Inc.
USHealthcareAs of 2026-10-09
Why SPRY matters now
ARS Pharmaceuticals, Inc. (SPRY) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.23 with -7.24% on the session and $420.1M in market capitalization; recent performance reads 1-month +34.59% and YTD -17.17%.
The latest financial table shown here is Q1 2026, with revenue of $22.7M, net income of $-60.6M, and EPS of $-0.61. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -18.3%.
The latest indexable market news headline is "SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $25.50; recent insider activity includes Fitzpatrick Alexander A filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
15.63
P/S
9.68
EV/EBITDA
-5.36
DCF Value
$-4.41
FCF Yield
-18.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.1%
Operating Margin
-204.5%
Net Margin
-200.0%
ROE
-153.6%
ROA
-68.8%
ROIC
-85.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $22.7M | $-60.6M | $-0.61 |
| Q4 2025 | $28.1M | $-41.3M | $-0.42 |
| FY 2025 | $84.3M | $-171.3M | $-1.74 |
| Q3 2025 | $32.5M | $-51.2M | $-0.52 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$25.50
Target (Median)
$25.50
Target Range
$25.00 - $26.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.83
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.